WO1998036730A3 - Compositions for treating acne rosacea - Google Patents

Compositions for treating acne rosacea Download PDF

Info

Publication number
WO1998036730A3
WO1998036730A3 PCT/EP1998/000991 EP9800991W WO9836730A3 WO 1998036730 A3 WO1998036730 A3 WO 1998036730A3 EP 9800991 W EP9800991 W EP 9800991W WO 9836730 A3 WO9836730 A3 WO 9836730A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
acne rosacea
treating acne
rosacea
prevention
Prior art date
Application number
PCT/EP1998/000991
Other languages
German (de)
French (fr)
Other versions
WO1998036730A2 (en
Inventor
Walter Diembeck
Udo Hoppe
Birgit Salzer
Gerhard Sauermann
Volker Steinkraus
Original Assignee
Beiersdorf Ag
Walter Diembeck
Udo Hoppe
Birgit Salzer
Gerhard Sauermann
Volker Steinkraus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19711565A external-priority patent/DE19711565A1/en
Application filed by Beiersdorf Ag, Walter Diembeck, Udo Hoppe, Birgit Salzer, Gerhard Sauermann, Volker Steinkraus filed Critical Beiersdorf Ag
Priority to JP53626998A priority Critical patent/JP2001512471A/en
Priority to EP98913571A priority patent/EP0969790A2/en
Publication of WO1998036730A2 publication Critical patent/WO1998036730A2/en
Publication of WO1998036730A3 publication Critical patent/WO1998036730A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Abstract

The invention concerns the use, in particular the topical use, of one or several compounds selected from the group of the NO-synthase inhibitors and their derivatives for the prevention and/or treatment of rosacea and acne rosacea.
PCT/EP1998/000991 1997-02-21 1998-02-20 Compositions for treating acne rosacea WO1998036730A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP53626998A JP2001512471A (en) 1997-02-21 1998-02-20 Preparations for the treatment of rosacea
EP98913571A EP0969790A2 (en) 1997-02-21 1998-02-20 Compositions for treating acne rosacea

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19706581 1997-02-21
DE19711565A DE19711565A1 (en) 1997-02-21 1997-03-20 Preparations for the treatment of rosacea
DE19711565.9 1997-03-20
DE19706581.3 1997-03-20

Publications (2)

Publication Number Publication Date
WO1998036730A2 WO1998036730A2 (en) 1998-08-27
WO1998036730A3 true WO1998036730A3 (en) 1998-10-22

Family

ID=26034114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/000991 WO1998036730A2 (en) 1997-02-21 1998-02-20 Compositions for treating acne rosacea

Country Status (3)

Country Link
EP (1) EP0969790A2 (en)
JP (1) JP2001512471A (en)
WO (1) WO1998036730A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19918750A1 (en) * 1999-04-24 2000-10-26 Beiersdorf Ag Active ingredients, cosmetic and dermatological preparations for improving the barrier function
FR2794974B1 (en) * 1999-06-16 2001-08-17 Exsymol Sa COSMETIC COMPOSITION FOR SLIMMING BASED ON L-ARGININE, AN ANALOG OF L-ARGININE OR A DERIVATIVE THEREOF, APPLICABLE TOPICALLY
FR2808189B1 (en) * 2000-04-28 2004-03-05 Oreal LIPOCHROMAN-6 AS NO-SYNTHASE INHIBITOR AND USES
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US8790712B2 (en) 2004-09-02 2014-07-29 Cosmo Oil Co., Ltd. Constitutional function-improving agents
JP4814567B2 (en) * 2004-09-02 2011-11-16 コスモ石油株式会社 Health function improver
JP4814568B2 (en) * 2004-09-02 2011-11-16 コスモ石油株式会社 Immune function improver
JP4814501B2 (en) * 2004-09-02 2011-11-16 コスモ石油株式会社 Antioxidant function improver
ES2653259T3 (en) * 2006-10-12 2018-02-06 Topaz Pharmaceuticals Inc. Topical formulations of ivermectin and removal procedures and prophylaxis of body lice
EP2116237A1 (en) * 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
JP2011063541A (en) * 2009-09-17 2011-03-31 Tokyo Institute Of Technology Purification method of l-arginine-binding factor and screening method of l-arginine-like compound
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
PT2552449T (en) 2010-03-26 2017-06-12 Galderma Res & Dev Compositions comprising brimonidine for the treatment of erythema
CA2792649A1 (en) 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
WO2012052479A2 (en) 2010-10-21 2012-04-26 Galderma S.A. Brimonidine gel compositions and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631776A1 (en) * 1993-07-02 1995-01-04 Roussel Uclaf Use of beta-naphthoquinone for accelerating the proliferation of endothelial cells and inhibiting no synthases
WO1995024884A1 (en) * 1994-03-16 1995-09-21 Handelman, Joseph, H. Inhibition of hair growth
WO1996026711A1 (en) * 1995-02-27 1996-09-06 L'oreal Nitric oxide synthase inhibitors
WO1997015280A1 (en) * 1995-10-26 1997-05-01 L'oreal Use of at least one no synthase inhibitor for treating sensitive skin
FR2744915A1 (en) * 1996-02-16 1997-08-22 Oreal Skin or hair treatment composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631776A1 (en) * 1993-07-02 1995-01-04 Roussel Uclaf Use of beta-naphthoquinone for accelerating the proliferation of endothelial cells and inhibiting no synthases
WO1995024884A1 (en) * 1994-03-16 1995-09-21 Handelman, Joseph, H. Inhibition of hair growth
WO1996026711A1 (en) * 1995-02-27 1996-09-06 L'oreal Nitric oxide synthase inhibitors
WO1997015280A1 (en) * 1995-10-26 1997-05-01 L'oreal Use of at least one no synthase inhibitor for treating sensitive skin
FR2744915A1 (en) * 1996-02-16 1997-08-22 Oreal Skin or hair treatment composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.A.QURESHI ET AL.: "From Bedside to the Bench and Back", ARCH. DERMATOL., vol. 132, no. 8, August 1996 (1996-08-01), pages 889 - 903, XP002075669 *
G.SAUERMANN ET AL.: "Influence of NO-Synthase Antagonists in Rosacea Patients", J.INVEST DERMATOL., vol. 108, no. 4, April 1997 (1997-04-01), pages 657, XP002075670 *
S.M.BIRNBAUM ET AL.: "Preparation of the Optical Isomers of Arginine, Histidine and S-Benzylcysteine by Asymmetric Enzymatic Hydrolysis of their Acetyl Derivatives", ARCH.BIOCHEM., vol. 39, 1952, pages 108 - 118, XP002075668 *

Also Published As

Publication number Publication date
WO1998036730A2 (en) 1998-08-27
JP2001512471A (en) 2001-08-21
EP0969790A2 (en) 2000-01-12

Similar Documents

Publication Publication Date Title
WO1998036730A3 (en) Compositions for treating acne rosacea
CA2267186A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2002047706A3 (en) Selective cox-2 inhibition from plant extracts
WO1996021655A3 (en) Substituted oxazolidine calpain and/or cathepsin b inhibitors
WO2000037107A3 (en) Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
WO2001051043A3 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
WO1999015167A3 (en) Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer
WO2003053383A3 (en) Cosmetic use of at least a hydrophobin for treating keratinous materials
WO1994004541A3 (en) Protein kinase inhibitors and related compounds combined with taxol
ZA973487B (en) Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment.
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2000009101A3 (en) Use of estrogenic compounds as anti-fungal agents
AU7629694A (en) Compositions for treating corns, calluses and warts
WO2000021513A3 (en) Methods for treating multiple sclerosis
AU8853998A (en) Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
WO1998018440A3 (en) Use of inhibitors of the activity of retinoic acid for treating sensitive skin
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
MXPA00007394A (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases.
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
EP1171145A4 (en) Use of catechin for preventing or treating coronary restenosis
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998913571

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 536269

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09367748

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998913571

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998913571

Country of ref document: EP